These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 39164557)

  • 1. Opicapone for the treatment of early wearing-off in levodopa-treated Parkinson's disease: pooled analysis of patient level data from two randomized open-label studies.
    Ferreira JJ; Lee JY; Ma HI; Jeon B; Poewe W; Antonini A; Stocchi F; Rodrigues DM; Fonseca MM; Castilla-Fernández G; Holenz J; Rocha JF; Rascol O;
    J Neurol; 2024 Oct; 271(10):6729-6738. PubMed ID: 39164557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opicapone to Treat Early Wearing-off in Parkinson's Disease Patients: The Korean ADOPTION Trial.
    Lee JY; Ma HI; Ferreira JJ; Rocha JF; Sung YH; Song IU; Ahn TB; Kwon DY; Cheon SM; Kim JM; Lee CS; Lee PH; Park JH; Lee JH; Park MY; Kim SJ; Baik JS; Choi SM; Shin HW; Lee HW; Kang SY; Jeon B
    Mov Disord Clin Pract; 2024 Jun; 11(6):655-665. PubMed ID: 38594812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
    Ferreira JJ; Rocha JF; Falcão A; Santos A; Pinto R; Nunes T; Soares-da-Silva P
    Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
    Lees AJ; Ferreira J; Rascol O; Poewe W; Rocha JF; McCrory M; Soares-da-Silva P;
    JAMA Neurol; 2017 Feb; 74(2):197-206. PubMed ID: 28027332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA.
    Lees AJ; Ferreira J; Rascol O; Reichmann H; Stocchi F; Tolosa E; Poewe W
    Expert Rev Neurother; 2017 Jul; 17(7):649-659. PubMed ID: 28580819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P
    Eur J Neurol; 2019 Jul; 26(7):953-960. PubMed ID: 30681754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Kwak N; Park J; Kang HY; Lee MJ; Suh JK; Lee H
    J Parkinsons Dis; 2022; 12(3):773-783. PubMed ID: 35180134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety Profile of Opicapone in the Management of Parkinson's Disease.
    Lees A; Ferreira JJ; Rocha JF; Rascol O; Poewe W; Gama H; Soares-da-Silva P
    J Parkinsons Dis; 2019; 9(4):733-740. PubMed ID: 31498127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study.
    Reichmann H; Lees A; Rocha JF; Magalhães D; Soares-da-Silva P;
    Transl Neurodegener; 2020 Mar; 9(1):9. PubMed ID: 32345378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 12-month prospective real-life study of opicapone efficacy and tolerability in Emirati and non-White subjects with Parkinson's disease based in United Arab Emirates.
    Metta V; Ibrahim H; Muralidharan N; Rodriguez K; Masagnay T; Mohan J; Lacsina A; Ahmed A; Benamer HTS; Chung-Faye G; Mrudula R; Falup-Pecurariu C; Rodriguez-Blazquez C; Borgohain R; Goyal V; Bhattacharya K; Chaudhuri KR
    J Neural Transm (Vienna); 2024 Jan; 131(1):25-30. PubMed ID: 37798410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial.
    Chaudhuri KR; Odin P; Ferreira JJ; Antonini A; Rascol O; Kurtis MM; Storch A; Bannister K; Soares-da-Silva P; Costa R; Magalhães D; Rocha JF
    BMC Neurol; 2022 Mar; 22(1):88. PubMed ID: 35279112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations.
    Takeda A; Takahashi R; Tsuboi Y; Nomoto M; Maeda T; Nishimura A; Yoshida K; Hattori N
    Mov Disord; 2021 Feb; 36(2):415-423. PubMed ID: 33073879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opicapone: Once-Daily COMT Inhibitor for the Treatment of Wearing Off in Parkinson's Disease.
    Craft BM; Baker DE; Levien TL
    Sr Care Pharm; 2022 Feb; 37(2):55-61. PubMed ID: 35082010
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term safety and efficacy of opicapone in Japanese Parkinson's patients with motor fluctuations.
    Takeda A; Takahashi R; Tsuboi Y; Nomoto M; Maeda T; Nishimura A; Yoshida K; Hattori N
    J Neural Transm (Vienna); 2021 Mar; 128(3):337-344. PubMed ID: 33630140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys.
    Bonifácio MJ; Sousa F; Soares-da-Silva P
    Eur J Pharmacol; 2021 Feb; 892():173742. PubMed ID: 33220276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of different catechol-o-methyl transferase inhibitors for patients with parkinson's disease: Systematic review and network meta-analysis.
    Wu W; Lu X; Zhang L; Hong D
    Clin Neurol Neurosurg; 2024 Apr; 239():108189. PubMed ID: 38437773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opicapone (Ongentys): A New COMT Inhibitor for the Treatment of Parkinson's Disease.
    St Onge E; Vanderhoof M; Miller S
    Ann Pharmacother; 2021 Sep; 55(9):1159-1166. PubMed ID: 33233916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OFF-times before, during, and after nighttime sleep periods in Parkinson's disease patients with motor fluctuations and the effects of opicapone: A post hoc analysis of diary data from BIPARK-1 and -2.
    Hauser RA; Videnovic A; Soares-da-Silva P; Liang GS; Olson K; Jen E; Rocha JF; Klepitskaya O
    Parkinsonism Relat Disord; 2024 Jun; 123():106971. PubMed ID: 38631081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opicapone Use in Clinical Practice across Germany: A Sub-Analysis of the OPTIPARK Study in Parkinson's Disease Patients with Motor Fluctuations.
    Reichmann H; Eggert K; Oehlwein C; Warnecke T; Lees AJ; Kemmer M; Soares-da-Silva P
    Eur Neurol; 2022; 85(5):389-397. PubMed ID: 35350024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.